Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01164150
Other study ID # CTRIAL-IE (ICORG) 09-06
Secondary ID CTRIAL-IE (ICORG
Status Terminated
Phase Phase 2
First received
Last updated
Start date March 2010
Est. completion date March 13, 2020

Study information

Verified date April 2023
Source Cancer Trials Ireland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Post-operative radiotherapy is internationally accepted as standard practice in the management of high-risk endometrial cancer1. Whilst it has no proven impact on overall survival it significantly increases local control. Conventional radiotherapy techniques (3-dimensional) utilise a 3 or 4 field beam arrangement to target the pelvis in order to treat those areas at risk of recurrence: the vagina, the parametrium and the pelvic lymph nodes. However, when using such a technique it is not possible to avoid irradiating sensitive normal tissues such as the bowel and bladder. Toxicity data from international randomised control trials in endometrial cancer report significantly more haematological, gastrointestinal, genitourinary and cutaneous toxicites (all grades) in those who received pelvic irradiation compared to those who did not2,3. These trials delivered radiotherapy using 2 or 3-dimensional techniques. Intensity Modulated Radiation Therapy (IMRT) is a newer but established radiotherapy technique in many tumour sites that allows us to much more tightly conform the radiation. It uses computer-generated beams to produce radiotherapy volumes that can avoid irradiation of normal tissues in the pelvis. There are no randomised studies reported in the literature that compare 3-dimensional pelvic irradiation with IMRT in patients who have had surgery for endometrial cancer. However there are several small studies that report considerable sparing of normal tissues using IMRT and when compared retrospectively with conventionally treated patients demonstrate marked reductions in acute gastrointestinal and genitourinary toxicity4. By delivering post-operative radiotherapy to the pelvis using IMRT (as opposed to the standard 3-dimensional technique) it is anticipated that whilst local control and survival will be unaffected acute and late toxicity will be reduced.


Description:

Primary Objective: • To compare the incidence of acute grade >2 GU and GI toxicity Secondary Objectives: - To establish in the context of a clinical research study the feasibility of implementing pelvic nodal irradiation using IMRT in gynaecological cancer - To establish an Image-Guided pathway for gynaecological cancer radiotherapy incorporating - Set-up errors and optimal margins for set-up uncertainty - Investigation of effects of bladder filling and rectal preparation protocols on the planning target volume - To estimate the rate of loco-regional control - To evaluate Quality of Life - To estimate the rate of disease-free survival - To estimate the overall survival rate - To compare the incidence of late GU and GI toxicity


Recruitment information / eligibility

Status Terminated
Enrollment 92
Est. completion date March 13, 2020
Est. primary completion date March 13, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients undergoing adjuvant pelvic radiotherapy for histologically confirmed endometrial adenocarcinoma / serous carcinoma / papillary serous carcinoma / mixed histology (adenocarcinoma and serous) and following AJCC 2009 grade/stage: - Grade 2: stage IB (LVSI +/or >60yrs) - Grade 3: stage IA and IB - Grade 1-3: Stage II and IIIA, IIIB and IIIC1 - Surgery consisting of total hysterectomy, +/- bilateral salpingo-oophorectomy, +/- lymph node sampling - Staging with imaging of pelvis and abdomen (either MRI or CT) - ECOG PS 0-2 - Age = 18 years - Provision of written informed consent in line with ICH-GCP guidelines Exclusion Criteria: - Previous radiotherapy to the pelvic region - Patients in whom concurrent chemotherapy in planned - Patients with macroscopic disease in situ - History of inflammatory bowel disease - Previous hip replacement - Previous bowel surgery (excluding appendectomy) - Patients with other syndromes/conditions associated with increased radiosensitivity - The patient has or had other co-existing malignancies within the past 5 years other than non-melanoma skin cancer - Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study or if it is felt by the research / medical team that the patient may not be able to comply with the protocol

Study Design


Intervention

Radiation:
45 Gy/25 fractions
Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy

Locations

Country Name City State
Ireland St Luke's Radiation Oncology Network (SLRON) Centres Dublin
Ireland St Luke's Centre for Radiation Oncology at St Lukes Hospital Dublin 6
Ireland St Luke's Centre for Radiation Oncology at St James Hospital Dublin 8
Ireland St Luke's Centre for Radiation Oncology at Beaumont Hospital Dublin 9
Ireland Mid-Western Radiation Oncology Centre Limerick

Sponsors (1)

Lead Sponsor Collaborator
Cancer Trials Ireland

Country where clinical trial is conducted

Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction in the incidence of = grade 2 acute genitourinary (GU) and gastrointestinal (GI) toxicity according to NCI CTCAE v.3.0 2015
Secondary Incidence of late GI and GU toxicity according to NCI CTCAE v.3.0 2015
Secondary Feasibility of implementing pelvic nodal irradiation using intensity-modulated radiotherapy in gynecological cancer 2015
Secondary Establishment of an image-guided pathway for gynecological cancer radiotherapy 2015
Secondary Rate of loco-regional control as assessed by CT scan, MRI, and biopsy 2015
Secondary Quality of life as assessed using EORTC QLQ-C30 and EORTC QLQ Cervical Cancer Specific Module CX 24 questionnaires 2015
Secondary Rate of disease-free survival 2015
Secondary Overall survival rate 2015
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05796518 - Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors N/A
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06463028 - Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Completed NCT03820024 - MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback N/A
Active, not recruiting NCT05082025 - Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Phase 2
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer
Completed NCT05378152 - Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity N/A
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Recruiting NCT04569773 - Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Not yet recruiting NCT06366347 - ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab Phase 2
Not yet recruiting NCT06073184 - Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium Phase 2
Not yet recruiting NCT05998798 - Revealing Engagement Patterns Among Endometrial Cancer Patients
Terminated NCT02907073 - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter Phase 1/Phase 2
Completed NCT02413606 - ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More? N/A